Pulse Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Pulse Biosciences has a total shareholder equity of $44.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $59.2M and $14.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$44.37m |
| Equity | US$44.36m |
| Total liabilities | US$14.79m |
| Total assets | US$59.15m |
Recent financial health updates
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Dec 25
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Sep 04Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Mar 08Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky
Apr 04Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?
Oct 29Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?
Mar 31Recent updates
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Dec 25We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Sep 04Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Mar 08Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO
Sep 20Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky
Apr 04Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?
Oct 29Pulse Biosciences gets Health Canada approval for CellFX System
Jun 09Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?
Mar 31Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
Feb 24Pulse Biosciences establishes at-the-market equity program
Feb 04What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?
Jan 20Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication
Jan 12We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Dec 16
Financial Position Analysis
Short Term Liabilities: PLSE's short term assets ($45.3M) exceed its short term liabilities ($6.7M).
Long Term Liabilities: PLSE's short term assets ($45.3M) exceed its long term liabilities ($8.1M).
Debt to Equity History and Analysis
Debt Level: PLSE is debt free.
Reducing Debt: PLSE had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PLSE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PLSE has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 15.1% each year.